NPORT-EX 2 c10900bnymello-november20191.htm Untitled Document

STATEMENT OF INVESTMENTS
BNY Mellon Research Growth Fund, Inc.

November 30, 2019 (Unaudited)

        
 

Description

   

Shares

 

Value ($)

 

Common Stocks - 98.3%

     

Capital Goods - 8.9%

     

AMETEK

   

205,642

 

20,360,614

 

Gardner Denver Holdings

   

744,242

a

25,207,477

 

Ingersoll-Rand

   

194,011

 

25,436,782

 

Rockwell Automation

   

127,236

 

24,917,898

 

United Technologies

   

232,242

 

34,450,778

 

W.W. Grainger

   

53,405

 

16,926,715

 
    

147,300,264

 

Consumer Services - 3.6%

     

Chipotle Mexican Grill

   

18,944

a

15,418,900

 

McDonald's

   

133,087

 

25,882,760

 

Wynn Resorts

   

152,120

 

18,383,702

 
    

59,685,362

 

Energy - 1.2%

     

Marathon Petroleum

   

317,802

 

19,271,513

 

Food & Staples Retailing - 1.1%

     

Walmart

   

154,087

 

18,350,221

 

Food, Beverage & Tobacco - 2.4%

     

PepsiCo

   

295,113

 

40,085,199

 

Health Care Equipment & Services - 7.3%

     

Alcon

   

247,214

a,b

13,668,462

 

Anthem

   

82,142

 

23,711,110

 

Baxter International

   

232,640

 

19,069,501

 

Boston Scientific

   

772,450

a

33,408,462

 

Danaher

   

135,554

 

19,788,173

 

Masimo

   

78,071

a

12,106,470

 
    

121,752,178

 

Insurance - 1.8%

     

American International Group

   

556,302

 

29,294,863

 

Materials - .8%

     

CF Industries Holdings

   

284,237

 

13,134,592

 

Media & Entertainment - 8.7%

     

Alphabet, Cl. C

   

75,966

a

99,132,591

 

Electronic Arts

   

120,922

a

12,214,331

 

Pinterest, Cl. A

   

669,642

a

13,044,626

 

Twitter

   

634,023

a

19,597,651

 
    

143,989,199

 

Pharmaceuticals Biotechnology & Life Sciences - 7.7%

     

Charles River Laboratories International

   

83,787

a

12,170,062

 

Eli Lilly & Co.

   

182,900

 

21,463,315

 


STATEMENT OF INVESTMENTS (Unaudited) (continued)

        
 

Description

   

Shares

 

Value ($)

 

Common Stocks - 98.3% (continued)

     

Pharmaceuticals Biotechnology & Life Sciences - 7.7% (continued)

     

Merck & Co.

   

476,834

 

41,570,388

 

Sage Therapeutics

   

60,198

a,b

9,316,844

 

Sarepta Therapeutics

   

141,546

a,b

15,922,510

 

Vertex Pharmaceuticals

   

65,270

a

14,473,623

 

Zoetis

   

103,728

 

12,501,299

 
    

127,418,041

 

Retailing - 8.2%

     

Amazon.com

   

59,392

a

106,953,114

 

O'Reilly Automotive

   

64,928

a

28,716,356

 
    

135,669,470

 

Semiconductors & Semiconductor Equipment - 8.7%

     

Advanced Micro Devices

   

574,734

a,b

22,500,836

 

Broadcom

   

135,959

 

42,991,595

 

Microchip Technology

   

168,042

b

15,886,691

 

Qualcomm

   

494,661

 

41,328,927

 

Xilinx

   

234,655

 

21,771,291

 
    

144,479,340

 

Software & Services - 25.5%

     

HubSpot

   

82,485

a

12,455,235

 

Microsoft

   

753,625

 

114,083,752

 

PayPal Holdings

   

348,254

a

37,614,915

 

Proofpoint

   

124,352

a

14,759,339

 

Salesforce.com

   

269,874

a

43,959,776

 

ServiceNow

   

87,820

a

24,856,573

 

Shopify, Cl. A

   

38,308

a

12,900,219

 

Splunk

   

205,788

a

30,707,685

 

Square, Cl. A

   

249,037

a,b

17,213,437

 

SS&C Technologies Holdings

   

362,106

 

21,744,465

 

Twilio, Cl. A

   

132,187

a,b

13,652,273

 

Visa, Cl. A

   

427,672

b

78,909,761

 
    

422,857,430

 

Technology Hardware & Equipment - 8.3%

     

Apple

   

371,258

 

99,218,700

 

Cognex

   

474,123

 

23,791,492

 

Zebra Technologies, Cl. A

   

60,316

a

15,135,697

 
    

138,145,889

 

Transportation - 2.0%

     

Union Pacific

   

190,012

 

33,440,212

 

Utilities - 2.1%

     

NextEra Energy

   

148,246

 

34,662,880

 

Total Common Stocks (cost $1,126,435,686)

   

1,629,536,653

 


        
 
  

1-Day
Yield (%)

     

Investment Companies - 1.6%

     

Registered Investment Companies - 1.6%

     

Dreyfus Institutional Preferred Government Plus Money Market Fund
(cost $26,476,590)

 

1.63

 

26,476,590

c

26,476,590

 

Total Investments (cost $1,152,912,276)

 

99.9%

 

1,656,013,243

 

Cash and Receivables (Net)

 

.1%

 

858,300

 

Net Assets

 

100.0%

 

1,656,871,543

 

a Non-income producing security.

b Security, or portion thereof, on loan. At November 30, 2019, the value of the fund’s securities on loan was $137,487,351 and the value of the collateral was $140,193,710, consisting of U.S. Government & Agency securities.

c Investment in affiliated issuer. The investment objective of this investment company is publicly available and can be found within the investment company’s prospectus.


STATEMENT OF INVESTMENTS
BNY Mellon Research Growth Fund, Inc.

November 30, 2019 (Unaudited)

The following is a summary of the inputs used as of November 30, 2019 in valuing the fund’s investments:

     
 

Level 1 - Unadjusted Quoted Prices

Level 2 - Other Significant Observable Inputs

Level 3 -Significant Unobservable Inputs

Total

Assets ($)

    

Investments in Securities:

  

Equity Securities—Common Stocks

1,629,536,653

-

-

1,629,536,653

Investment Companies

26,476,590

-

-

26,476,590

See Statement of Investments for additional detailed categorizations, if any.


NOTES

The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the exclusive reference of authoritative U.S. generally accepted accounting principles (“GAAP”) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under authority of federal laws are also sources of authoritative GAAP for SEC registrants. The fund is an investment company and applies the accounting and reporting guidance of the FASB ASC Topic 946 Financial Services-Investment Companies. The fund’s financial statements are prepared in accordance with GAAP, which may require the use of management estimates and assumptions. Actual results could differ from those estimates.

The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., the exit price). GAAP establishes a fair value hierarchy that prioritizes the inputs of valuation techniques used to measure fair value. This hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

Additionally, GAAP provides guidance on determining whether the volume and activity in a market has decreased significantly and whether such a decrease in activity results in transactions that are not orderly. GAAP requires enhanced disclosures around valuation inputs and techniques used during annual and interim periods.

Various inputs are used in determining the value of the fund’s investments relating to fair value measurements. These inputs are summarized in the three broad levels listed below:

Level 1—unadjusted quoted prices in active markets for identical investments.

Level 2—other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.).

Level 3—significant unobservable inputs (including the fund’s own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy. Valuation techniques used to value the fund’s investments are as follows:

Investments in equity securities are valued at the last sales price on the securities exchange or national securities market on which such securities are primarily traded. Securities listed on the National Market System for which market quotations are available are valued at the official closing price or, if there is no official closing price that day, at the last sales price. For open short positions, asked prices are used for valuation


NOTES

purposes. Bid price is used when no asked price is available. Registered investment companies that are not traded on an exchange are valued at their net asset value. All of the preceding securities are generally categorized within Level 1 of the fair value hierarchy.

Securities not listed on an exchange or the national securities market, or securities for which there were no transactions, are valued at the average of the most recent bid and asked prices. U.S. Treasury Bills are valued at the mean price between quoted bid prices and asked prices by an independent pricing service (the “Service”) approved by the Board Members (“Board”).These securities are generally categorized within Level 2 of the fair value hierarchy.

The Service’s procedures are reviewed by BNY Mellon under the general supervision of the Board.

Fair valuing of securities may be determined with the assistance of a pricing service using calculations based on indices of domestic securities and other appropriate indicators, such as prices of relevant American Depository Receipts and futures. Utilizing these techniques may result in transfers between Level 1 and Level 2 of the fair value hierarchy.

When market quotations or official closing prices are not readily available, or are determined not to accurately reflect fair value, such as when the value of a security has been significantly affected by events after the close of the exchange or market on which the security is principally traded (for example, a foreign exchange or market), but before the fund calculates its net asset value, the fund may value these investments at fair value as determined in accordance with the procedures approved by the Board. Certain factors may be considered when fair valuing investments such as: fundamental analytical data, the nature and duration of restrictions on disposition, an evaluation of the forces that influence the market in which the securities are purchased and sold, and public trading in similar securities of the issuer or comparable issuers. These securities are either categorized within Level 2 or 3 of the fair value hierarchy depending on the relevant inputs used.

For restricted securities where observable inputs are limited, assumptions about market activity and risk are used and such securities are generally categorized within Level 3 of the fair value hierarchy.

Pursuant to a securities lending agreement with The Bank of New York Mellon, a subsidiary of BNY Mellon and an affiliate of BNY Mellon Investment Adviser, Inc., the fund may lend securities to qualified institutions. It is the fund’s policy that, at origination, all loans are secured by collateral of at least 102% of the value of U.S. securities loaned and 105% of the value of foreign securities loaned. Collateral equivalent to at least 100% of the market value of securities on loan is maintained at all times. Collateral is either in the form of cash, which can be invested in certain money market mutual funds managed by BNY Mellon Investment Adviser Inc., or U.S. Government and Agency securities. The fund is entitled to receive all dividends, interest and distributions on securities loaned, in addition to income earned as a


NOTES

result of the lending transaction. Should a borrower fail to return the securities in a timely manner, The Bank of New York Mellon is required to replace the securities for the benefit of the fund or credit the fund with the market value of the unreturned securities and is subrogated to the fund’s rights against the borrower and the collateral. Additionally, the contractual maturity of security lending transactions are on an overnight and continuous basis.

At November 30, 2019, accumulated net unrealized appreciation on investments was $503,100,967, consisting of $519,929,516 gross unrealized appreciation and $16,828,549 gross unrealized depreciation.

At November 30, 2019, the cost of investments for federal income tax purposes was substantially the same as the cost for financial reporting purposes (see the Statement of Investments).

Additional investment related disclosures are hereby incorporated by reference to the annual and semi-annual reports previously filed with the SEC on Form N-CSR.